IN8bio Q3 net loss narrows to $3.9 mln, R&D expenses down

Reuters11-07

IN8bio Q3 net loss narrows to $3.9 mln, R&D expenses down

Overview

IN8bio Q3 net loss narrows to $3.9 mln from $7.1 mln last year
R&D expenses for Q3 decreased due to strategic pause in INB-400 program
Company expanded INB-100 trial to accelerate enrollment at multiple sites

Outlook

IN8bio to present updated INB-200/400 data at SNO Annual Meeting, Nov 19-23, 2025
Additional INB-619 preclinical data to be presented at ASH Annual Meeting, Dec 6-9, 2025

Result Drivers

R&D EXPENSES - Expenses fell to $2.1 mln from $3.3 mln due to pause on clinical trial-related activities for the INB-400 program last year and personnel-related costs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$3.85 mln
Q3 Basic EPS		-$0.85
Q3 Operating Expenses		$3.97 mln
Q3 Operating Income		-$3.85 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for IN8bio Inc is $7.00, about 76.7% above its November 5 closing price of $1.63

Press Release: ID:nGNX1KqHtc

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581438150?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581438150","market":"nz","top_or_hot":-1,"title":"IN8bio Q3 net loss narrows to $3.9 mln, R&D expenses down","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>IN8bio Q3 net loss narrows to $3.9 mln, R&amp;D expenses down</title></head><body><p><span>Overview</span></p><ul><li><p>IN8bio Q3 net loss narrows to $3.9 mln from $7.1 mln last year</p></li><li><p>R&amp;D expenses for Q3 decreased due to strategic pause in INB-400 program</p></li><li><p>Company expanded INB-100 trial to accelerate enrollment at multiple sites</p></li></ul><p><span>Outlook</span></p><ul><li><p>IN8bio to present updated INB-200/400 data at SNO Annual Meeting, Nov 19-23, 2025</p></li><li><p>Additional INB-619 preclinical data to be presented at ASH Annual Meeting, Dec 6-9, 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Expenses fell to $2.1 mln from $3.3 mln due to pause on clinical trial-related activities for the INB-400 program last year and personnel-related costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$3.85 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.85</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$3.97 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$3.85 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for IN8bio Inc is $7.00, about 76.7% above its November 5 closing price of $1.63</p></li></ul><p>Press Release: <span>ID:nGNX1KqHtc</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IN8bio Q3 net loss narrows to $3.9 mln, R&D expenses down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIN8bio Q3 net loss narrows to $3.9 mln, R&D expenses down\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>IN8bio Q3 net loss narrows to $3.9 mln, R&amp;D expenses down</title></head><body><p><span>Overview</span></p><ul><li><p>IN8bio Q3 net loss narrows to $3.9 mln from $7.1 mln last year</p></li><li><p>R&amp;D expenses for Q3 decreased due to strategic pause in INB-400 program</p></li><li><p>Company expanded INB-100 trial to accelerate enrollment at multiple sites</p></li></ul><p><span>Outlook</span></p><ul><li><p>IN8bio to present updated INB-200/400 data at SNO Annual Meeting, Nov 19-23, 2025</p></li><li><p>Additional INB-619 preclinical data to be presented at ASH Annual Meeting, Dec 6-9, 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Expenses fell to $2.1 mln from $3.3 mln due to pause on clinical trial-related activities for the INB-400 program last year and personnel-related costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$3.85 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.85</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$3.97 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$3.85 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for IN8bio Inc is $7.00, about 76.7% above its November 5 closing price of $1.63</p></li></ul><p>Press Release: <span>ID:nGNX1KqHtc</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INAB","symbol_name":"IN8bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1I0:1","article_id":"2581438150","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581438150","pubTimestamp":1762464327,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IN8bio Q3 net loss narrows to $3.9 mln, R&D expenses downOverviewIN8bio Q3 net loss narrows to $3.9 mln from $7.1 mln last yearR&D expenses for Q3 decreased due to strategic pause in INB-400 programCo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INAB":"IN8bio, Inc.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"IN8bio第三季度净亏损收窄至390万美元，研发费用下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INAB":0.9},"content_text":"IN8bio Q3 net loss narrows to $3.9 mln, R&D expenses downOverviewIN8bio Q3 net loss narrows to $3.9 mln from $7.1 mln last yearR&D expenses for Q3 decreased due to strategic pause in INB-400 programCompany expanded INB-100 trial to accelerate enrollment at multiple sitesOutlookIN8bio to present updated INB-200/400 data at SNO Annual Meeting, Nov 19-23, 2025Additional INB-619 preclinical data to be presented at ASH Annual Meeting, Dec 6-9, 2025Result DriversR&D EXPENSES - Expenses fell to $2.1 mln from $3.3 mln due to pause on clinical trial-related activities for the INB-400 program last year and personnel-related costsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$3.85 mlnQ3 Basic EPS-$0.85Q3 Operating Expenses$3.97 mlnQ3 Operating Income-$3.85 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"Wall Street's median 12-month price target for IN8bio Inc is $7.00, about 76.7% above its November 5 closing price of $1.63Press Release: ID:nGNX1KqHtcFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581438150","isCrawlerRequest":true}